In Brief: Quintiles
Executive Summary
Quintiles: Definitive agreement to acquire CerebroVascular Advances announced by Research Triangle Park, N.C.-based Quintiles May 8. Quintiles will issue 251,000 shares valued at approximately $14 mil. to fund the acquisition. The merger is expected to be completed later this year. Quintiles said that it expects to retain CVA CEO David Edwards and Chief Operating Officer Mike Dwyer. San Antonio-based CVA is a clinical research company specializing in stroke trials and had net income of $1.3 mil. on revenues of $4.5 mil. in 1996...